WATERTOWN, Mass.--(BUSINESS WIRE)--Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments.

马萨诸塞州沃特敦（商业新闻短讯）--马里亚纳肿瘤公司是一家全面整合的生物技术公司，开创了治疗癌症患者的放射性药物创新的新时代，今天宣布它将被诺华以10亿美元的预付款和高达7.5亿美元的潜在里程碑付款收购。

The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis..

此次收购将马里亚纳肿瘤学创新的放射性药物管道和平台与诺华已证实的临床开发和商业化专业知识结合在一起。。

Mariana Oncology has developed a robust portfolio of novel peptide based-radiopharmaceuticals targeting a broad spectrum of solid tumor cancers, and has invested in manufacturing capabilities, an extensive isotope supply chain and novel formulations to enhance final product shelf-life. The company’s lead program, MC-339, is a novel radioligand therapy (RLT) designed to target small cell lung cancer..

马里亚纳肿瘤学已经开发出针对广泛实体瘤癌症的新型肽基放射性药物的强大组合，并投资于制造能力，广泛的同位素供应链和新配方，以提高最终产品的保质期。该公司的领先项目MC-339是一种新型放射性配体疗法（RLT），旨在靶向小细胞肺癌。。

“Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach. Together, we offer a compelling combination of capabilities,” said Simon Read, Founder and CEO, Mariana Oncology. “In the short time since founding the company, the team at Mariana Oncology has developed a leading radiopharmaceutical discovery platform and an innovative pipeline.

Mariana Oncology创始人兼首席执行官西蒙·里德（Simon Read）表示：“诺华是放射性药物商业化领域的公认领导者，拥有世界级的团队和全球影响力。我们共同提供了令人信服的能力组合。”。“在公司成立后的短时间内，马里亚纳肿瘤学团队开发了领先的放射性药物发现平台和创新管道。

Our strategy has centered on overcoming the unique challenges of end-to-end radiopharmaceutical R&D and ultimately, delivery of these drugs to the bedside. Both Mariana and Novartis are committed to transforming cancer care, and together we will be in a better position to do that.”.

我们的战略集中于克服端到端放射性药物研发的独特挑战，并最终将这些药物输送到床边。马里亚纳和诺华都致力于改变癌症治疗，我们一起将处于更好的位置。”。

“This acquisition of Mariana Oncology brings to Novartis phenomenal talent and new capabilities in radioligand therapeutic research that complement our wide-ranging internal research and drug discovery efforts, in addition to our translational and clinical development capabilities,” said Shiva Malek, PhD, Global Head of Oncology for Biomedical Research at Novartis.

诺华生物医学研究肿瘤学全球负责人Shiva Malek博士说：“此次收购马里亚纳肿瘤学为诺华带来了非凡的人才和放射性配体治疗研究方面的新能力，这些能力补充了我们广泛的内部研究和药物发现工作，以及我们的转化和临床开发能力。”。

“This is an ideal pairing, and we are thrilled to continue to do pioneering science together, translating RLT discovery into clinical development to deliver transformative therapies to patients.”.

“这是一对理想的搭档，我们很高兴能继续一起做开创性的科学，将RLT的发现转化为临床开发，为患者提供变革性治疗。”。

Mariana was founded in 2021 by Atlas Venture, Access Biotechnology and RA Capital Management, and has raised additional funds from other top investors including DeepTrack Capital and Forbion.

Mariana由Atlas Venture、Access Biotechnology和RA Capital Management于2021年成立，并从包括DeepTrack Capital和Forbion在内的其他顶级投资者那里筹集了额外资金。

The transaction is subject to customary closing conditions.

该交易受惯例成交条件的约束。

Centerview Partners LLC served as financial advisor, and Goodwin Procter as legal counsel to Mariana Oncology on the transaction.

Centerview Partners LLC担任财务顾问，Goodwin Procter担任Mariana Oncology的法律顾问。

About Mariana Oncology

关于马里亚纳肿瘤学

Mariana Oncology is a fully integrated, radiopharmaceutical company pioneering a new standard of care in cancer treatment – targeted peptide-based radioligand therapeutics (RLTs) designed to maximize tumor penetration while minimizing toxicity. Mariana is comprised of some of the world’s leading experts in radiopharmaceutical science and manufacturing who together are pioneering innovations in end-to-end discovery, development and delivery of radioligand therapeutics.

Mariana Oncology是一家全面整合的放射性制药公司，开创了癌症治疗的新标准-靶向肽基放射性配体疗法（RLT），旨在最大程度地提高肿瘤穿透率，同时最大程度地降低毒性。Mariana由一些世界领先的放射性药物科学和制造专家组成，他们共同开创了放射性配体治疗剂端到端发现，开发和交付的创新。

The company has developed a portfolio of novel RLTs designed to target a broad range of difficult-to-treat cancers. Mariana’s lead program, MC-339, is an actinium-based radioligand therapeutic being investigated to treat small cell lung cancer..

该公司开发了一系列新型RLT，旨在针对各种难以治疗的癌症。马里亚纳的主要项目MC-339是一种基于锕的放射性配体治疗剂，正在研究用于治疗小细胞肺癌。。